Universe Pharma Posts $9M Revenue, $1.6M Loss; Unveils $10.75M All-Stock Deal
UPC sits 63% above its 52-week low of $2.
Summary
Universe Pharmaceuticals reported a narrower loss for the six months ended March 31, 2026, and disclosed a $10.75 million all-stock acquisition of Best Praise International.
Key Events · Earnings and Guidance · UPC
-
Revenue Flat, Loss Narrows
Revenue was $9.04 million, down 1.3% year-over-year. Net loss improved to $1.55 million from $3.28 million, primarily due to a $1.58 million decrease in consulting fees.
-
Cash Position Declines
Cash fell to $27.6 million from $33.6 million at September 30, 2025, driven by a $5.2 million deposit for the Best Praise acquisition and negative operating cash flow of $4.3 million.
-
$10.75M All-Stock Acquisition Announced
The company entered a Share Purchase Agreement to acquire Best Praise International for $10.75 million, payable entirely through the issuance of 4,376,552 Class A ordinary shares. The deal is expected to close in the second half of 2026.
-
CEO Receives 84,500 Shares Under New Equity Plan
The 2026 Equity Incentive Plan was adopted, and CEO Gang Lai was granted 71,890 Class A shares and 12,610 Class B shares as compensation for past services.
Analysis · UPC · Life Sciences
Universe Pharmaceuticals filed unaudited results for the six months ended March 31, 2026. Revenue held roughly flat at $9.04 million, but the net loss narrowed to $1.55 million from $3.28 million a year earlier, driven by a sharp drop in consulting fees. The company ended the period with $27.6 million in cash. More importantly, the filing reveals two subsequent events: the adoption of a 2026 Equity Incentive Plan and the grant of 84,500 shares to CEO Gang Lai, and a definitive agreement to acquire Best Praise International for $10.75 million, payable entirely in newly issued Class A shares. The all-stock acquisition, if completed, would significantly expand the company's footprint but also introduce substantial dilution for existing holders.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.8% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, UPC was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $2.00 to $17.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.